Cambridge Nutritional Sciences (FRA:RVKA) EBITDA per Share: €0.01 (TTM As of Sep. 2025)


What is Cambridge Nutritional Sciences EBITDA per Share?

Cambridge Nutritional Sciences FRA:RVKA EBITDA per Share is €0.01 as of Sep. 2025. The stock has 3 warning signs investors should review. Among 694 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 93.37% on this metric.

Cambridge Nutritional Sciences's EBITDA per Share for the six months ended in Sep. 2025 was €0.00. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 was €0.01.

During the past 12 months, the average EBITDA per Share Growth Rate of Cambridge Nutritional Sciences was 350.00% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 65.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Cambridge Nutritional Sciences's EBITDA per Share or its related term are showing as below:

FRA:RVKA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45   Med: 0   Max: 65.1
Current: 65.1

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Cambridge Nutritional Sciences was 65.10% per year. The lowest was -45.00% per year. And the median was 0.00% per year.

FRA:RVKA's 3-Year EBITDA Growth Rate is ranked better than
93.37% of 694 companies
in the Medical Devices & Instruments industry
Industry Median: 7.8 vs FRA:RVKA: 65.10

Cambridge Nutritional Sciences's EBITDA for the six months ended in Sep. 2025 was €-0.08 Mil.

During the past 12 months, the average EBITDA Growth Rate of Cambridge Nutritional Sciences was 394.10% per year. During the past 3 years, the average EBITDA Growth Rate was 82.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Cambridge Nutritional Sciences was 82.80% per year. The lowest was -46.50% per year. And the median was 21.20% per year.


Cambridge Nutritional Sciences  (FRA:RVKA) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Cambridge Nutritional Sciences EBITDA per Share Related Terms


Cambridge Nutritional Sciences EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Cambridge Nutritional Sciences's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambridge Nutritional Sciences EBITDA per Share Chart

Cambridge Nutritional Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.01 0.00 0.01

Cambridge Nutritional Sciences Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.01 0.00

Cambridge Nutritional Sciences EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cambridge Nutritional Sciences's EBITDA per Share for the fiscal year that ended in Mar. 2025 is calculated as

EBITDA per Share(A: Mar. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=2.627/238.271
=0.01

Cambridge Nutritional Sciences's EBITDA per Share for the quarter that ended in Sep. 2025 is calculated as

EBITDA per Share(Q: Sep. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.076/238.271
=-0.00

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of €0.01 mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a EBITDA per Share of €0.01 as of Sep. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #46 out of 694 companies in the Medical Devices & Instruments industry, placing it in the top 6.6%.
Is Cambridge Nutritional Sciences' EBITDA per Share too high?
Cambridge Nutritional Sciences' current EBITDA per Share is €0.01. Based on the distribution chart, Cambridge Nutritional Sciences ranks #46 out of 694 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' EBITDA per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #46 out of 694 companies for EBITDA per Share. This places Cambridge Nutritional Sciences in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Medical Devices & Instruments company?
The median EBITDA per Share among Medical Devices & Instruments companies is 7.80, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median EBITDA per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current EBITDA per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Cambridge Nutritional Sciences (FRA:RVKA) has a current EBITDA per Share of €0.01. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current EBITDA per Share is €0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current EBITDA per Share is €0.01 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges CNSL:UK
Address One Fleet Place, London, GBR, EC4M 7WS
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.